|
AU2008317354B2
(en)
|
2007-10-25 |
2014-04-10 |
Ospedale San Raffaele S.R.L. |
Methods and compositions for targeted integration
|
|
EP2281050B1
(en)
|
2008-04-14 |
2014-04-02 |
Sangamo BioSciences, Inc. |
Linear donor constructs for targeted integration
|
|
CA2741119C
(en)
*
|
2008-10-29 |
2019-02-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
|
WO2010065123A1
(en)
|
2008-12-04 |
2010-06-10 |
Sangamo Biosciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
CA2747124C
(en)
*
|
2008-12-17 |
2018-09-04 |
Dow Agrosciences Llc |
Targeted integration into the zp15 locus
|
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
WO2011007193A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Cellectis |
Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
|
|
CA2770312A1
(en)
|
2009-08-11 |
2011-02-17 |
Sangamo Biosciences, Inc. |
Organisms homozygous for targeted modification
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
MX336846B
(es)
*
|
2010-01-22 |
2016-02-03 |
Sangamo Biosciences Inc |
Alteracion genomica dirigida.
|
|
AU2011215557B2
(en)
|
2010-02-09 |
2016-03-10 |
Sangamo Therapeutics, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
WO2011139336A1
(en)
|
2010-04-26 |
2011-11-10 |
Sangamo Biosciences, Inc. |
Genome editing of a rosa locus using nucleases
|
|
KR101974036B1
(ko)
|
2010-05-03 |
2019-04-30 |
상가모 테라퓨틱스, 인코포레이티드 |
아연 핑거 모듈을 연결하기 위한 조성물
|
|
EP2571512B1
(en)
|
2010-05-17 |
2017-08-23 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
US8945868B2
(en)
*
|
2010-07-21 |
2015-02-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of a HLA locus
|
|
WO2012047598A1
(en)
|
2010-09-27 |
2012-04-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
ES2562421T3
(es)
|
2010-10-12 |
2016-03-04 |
The Children's Hospital Of Philadelphia |
Métodos y composiciones para tratar la hemofilia B
|
|
AU2012286901B2
(en)
|
2011-07-25 |
2016-10-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
IL293650B2
(en)
|
2011-09-21 |
2024-10-01 |
Sangamo Therapeutics Inc |
Methods and compositions for regulation of transgene expression
|
|
AU2012328682B2
(en)
|
2011-10-27 |
2017-09-21 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of the HPRT locus
|
|
WO2013158309A2
(en)
*
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
|
KR101904508B1
(ko)
|
2012-04-25 |
2018-10-04 |
리제너론 파마슈티칼스 인코포레이티드 |
큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화
|
|
US10174331B2
(en)
|
2012-05-07 |
2019-01-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
CA2878037C
(en)
|
2012-07-11 |
2021-08-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
AU2013289206B2
(en)
|
2012-07-11 |
2018-08-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
SG11201500852WA
(en)
|
2012-08-29 |
2015-04-29 |
Sangamo Biosciences Inc |
Methods and compositions for treatment of a genetic condition
|
|
CA2886684C
(en)
|
2012-10-10 |
2023-09-19 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014081855A1
(en)
*
|
2012-11-20 |
2014-05-30 |
Universite De Montreal |
Methods and compositions for muscular dystrophies
|
|
EP2929017A4
(en)
*
|
2012-12-05 |
2016-09-28 |
Sangamo Biosciences Inc |
METHOD AND COMPOSITIONS FOR REGULATING METABOLISM DISEASES
|
|
BR102013032200A2
(pt)
|
2012-12-13 |
2015-11-24 |
Dow Agrosciences Llc |
direcionamento preciso de um gene para um locus específico em milho
|
|
JP6491113B2
(ja)
|
2013-02-25 |
2019-03-27 |
サンガモ セラピューティクス， インコーポレイテッド |
ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
|
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
KR20200136508A
(ko)
|
2013-04-16 |
2020-12-07 |
리제너론 파마슈티칼스 인코포레이티드 |
랫트 게놈의 표적화된 변형
|
|
AU2014262867B2
(en)
*
|
2013-05-10 |
2019-12-05 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
WO2014186585A2
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
MX391904B
(es)
|
2013-11-11 |
2025-03-12 |
Sangamo Biosciences Inc |
Un represor genetico para usarse en el tratamiento de la enfermedad de huntington.
|
|
WO2015073683A2
(en)
|
2013-11-13 |
2015-05-21 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
DK3080274T3
(da)
|
2013-12-09 |
2020-08-31 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til genom-manipulation
|
|
JP6174811B2
(ja)
|
2013-12-11 |
2017-08-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ゲノムの標的改変のための方法及び組成物
|
|
DK3102673T3
(da)
|
2014-02-03 |
2020-07-06 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
|
|
KR20150096064A
(ko)
*
|
2014-02-14 |
2015-08-24 |
서울대학교산학협력단 |
Ｍｄｃｋ ⅱ 세포의 크로모좀에서 ａａｖｓ1 위치를 인식하고 이곳에 외래 유전자를 도입하여 안정하게 발현시키는 방법
|
|
CA2939942A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
CA2939847C
(en)
|
2014-03-21 |
2023-09-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
US20170037431A1
(en)
*
|
2014-05-01 |
2017-02-09 |
University Of Washington |
In vivo Gene Engineering with Adenoviral Vectors
|
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
|
BR112016025849A2
(pt)
|
2014-05-08 |
2017-10-17 |
Chdi Foundation Inc |
métodos e composições para o tratamento da doença de huntington
|
|
US9574211B2
(en)
|
2014-05-13 |
2017-02-21 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
WO2015188056A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
|
RU2704283C9
(ru)
|
2014-06-06 |
2020-02-07 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для модификации целевого локуса
|
|
PT3161128T
(pt)
|
2014-06-26 |
2018-11-21 |
Regeneron Pharma |
Métodos e composições para modificações genéticas alvejadas e métodos de utilização
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
CN113699113A
(zh)
|
2014-09-16 |
2021-11-26 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
EP3207124B1
(en)
|
2014-10-15 |
2019-06-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
|
EP3521437B1
(en)
|
2014-11-21 |
2025-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for targeted genetic modification using paired guide rnas
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
SG11201704646YA
(en)
|
2014-12-19 |
2017-07-28 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
|
US20180002379A1
(en)
|
2015-01-21 |
2018-01-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
US20180022781A1
(en)
|
2015-02-13 |
2018-01-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
MX382223B
(es)
|
2015-05-12 |
2025-03-13 |
Sangamo Therapeutics Inc |
Regulacion de expresion genica mediada por nucleasa.
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
CA2991301A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
JP6713691B2
(ja)
*
|
2015-08-20 |
2020-07-01 |
大学共同利用機関法人情報・システム研究機構 |
動物細胞ゲノム部位特異的外来ｄｎａ挿入方法及び前記挿入方法を用いて得られる細胞
|
|
RS66924B1
(sr)
|
2015-09-23 |
2025-07-31 |
Sangamo Therapeutics Inc |
Htt represori i njihova upotreba
|
|
AU2016343887B2
(en)
|
2015-10-28 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
|
|
AU2016361350B2
(en)
|
2015-11-23 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
EP3389677B1
(en)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
|
AU2016374253B2
(en)
|
2015-12-18 |
2021-10-21 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the MHC cell receptor
|
|
CA3010738A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
CA3011049A1
(en)
|
2016-02-02 |
2017-08-10 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
CN106148286B
(zh)
*
|
2016-06-29 |
2019-10-29 |
牛刚 |
一种用于检测热原的细胞模型的构建方法和细胞模型及热原检测试剂盒
|
|
CA3034882A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
BR112019003327A2
(pt)
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics, Inc. |
nucleases manipuladas de alvo específico
|
|
EP3509645A4
(en)
|
2016-09-07 |
2020-06-17 |
Sangamo Therapeutics, Inc. |
MODULATION OF LIVER GENES
|
|
EP3528852B1
(en)
|
2016-10-20 |
2025-09-03 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
|
AU2017347928A1
(en)
|
2016-10-31 |
2019-05-09 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
AU2018219895C1
(en)
*
|
2017-02-09 |
2024-10-03 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
|
CN106978438B
(zh)
*
|
2017-02-27 |
2020-08-28 |
北京大北农生物技术有限公司 |
提高同源重组效率的方法
|
|
EP4410317A3
(en)
|
2017-04-28 |
2024-10-30 |
Acuitas Therapeutics Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
JP2020518245A
(ja)
|
2017-05-03 |
2020-06-25 |
サンガモ セラピューティクス， インコーポレイテッド |
嚢胞性線維症膜貫通コンダクタンス制御因子（ｃｆｔｒ）遺伝子の改変のための方法および組成物
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
US20190032156A1
(en)
|
2017-07-31 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
|
BR112020001364A2
(pt)
|
2017-07-31 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
métodos para testar e modificar a capacidade de uma crispr/cas nuclease.
|
|
WO2019028023A2
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS AND COMPOSITIONS FOR EVALUATING CRISPR / CAS MEDIATED DISRUPTION OR EXCISION AND CRISPR / CAS INDUCED RECOMBINATION USING IN VIVO EXOGENIC DONOR NUCLEIC ACID
|
|
JP2021502085A
(ja)
|
2017-11-09 |
2021-01-28 |
サンガモ セラピューティクス， インコーポレイテッド |
サイトカイン誘導性ｓｈ２含有タンパク質（ｃｉｓｈ）遺伝子の遺伝子改変
|
|
CA3089587A1
(en)
|
2018-02-08 |
2019-08-15 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
CN112041432A
(zh)
|
2018-02-15 |
2020-12-04 |
纪念斯隆-凯特林癌症中心 |
Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
|
|
WO2019183123A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
US20210015869A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
US11421007B2
(en)
|
2018-04-18 |
2022-08-23 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (Htt)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
CN112867792A
(zh)
|
2018-08-23 |
2021-05-28 |
桑格摩生物治疗股份有限公司 |
工程化靶特异性碱基编辑器
|
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
|
KR20210060533A
(ko)
|
2018-09-18 |
2021-05-26 |
상가모 테라퓨틱스, 인코포레이티드 |
프로그램화된 세포 사멸 1 (pd1) 특이적 뉴클레아제
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
|
EP3867380A2
(en)
|
2018-10-18 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor ix
|
|
TW202028461A
(zh)
|
2018-10-18 |
2020-08-01 |
美商英特利亞醫療公司 |
核酸構築體及使用方法
|
|
KR20210123289A
(ko)
|
2018-11-21 |
2021-10-13 |
인답타 세라뷰틱스 인코포레이티드 |
자연 살해 세포 서브세트의 증식을 위한 방법 및 관련 조성물 및 방법
|
|
KR20210094609A
(ko)
|
2018-11-28 |
2021-07-29 |
포티 세븐, 인코포레이티드 |
절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US20220098621A1
(en)
|
2019-02-05 |
2022-03-31 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
|
WO2020163307A1
(en)
|
2019-02-06 |
2020-08-13 |
Emendobio Inc. |
New engineered high fidelity cas9
|
|
BR112021019512A2
(pt)
|
2019-04-03 |
2022-02-15 |
Regeneron Pharma |
Métodos para inserir uma sequência de codificação de proteína de ligação ao antígeno e para tratar ou efetuar a profilaxia de uma doença em um animal, animal, célula, genoma, ácido nucleico doador exógeno, gene de porto seguro, e, agente de nuclease ou um ou mais ácidos nucleicos
|
|
EP3962519A1
(en)
|
2019-05-01 |
2022-03-09 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
KR20220016475A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
|
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
|
WO2021072115A1
(en)
|
2019-10-08 |
2021-04-15 |
Regents Of The University Of Minnesota |
Crispr-mediated human genome editing with vectors
|
|
AU2020379046B2
(en)
|
2019-11-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
GB202007577D0
(en)
|
2020-05-21 |
2020-07-08 |
Oxford Genetics Ltd |
Hdr enhancers
|
|
EP4153741A1
(en)
|
2020-05-21 |
2023-03-29 |
Oxford Genetics Limited |
Hdr enhancers
|
|
EP4153739A1
(en)
|
2020-05-21 |
2023-03-29 |
Oxford Genetics Limited |
Hdr enhancers
|
|
GB202007578D0
(en)
|
2020-05-21 |
2020-07-08 |
Univ Oxford Innovation Ltd |
Hdr enhancers
|
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2022011099A1
(en)
|
2020-07-08 |
2022-01-13 |
Regents Of The University Of Minnesota |
Modified hexosaminidase and uses thereof
|
|
FI4182297T3
(fi)
|
2020-07-16 |
2025-12-05 |
Acuitas Therapeutics Inc |
Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
|
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
US12305184B2
(en)
|
2021-09-03 |
2025-05-20 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
MX2024005124A
(es)
|
2021-10-27 |
2024-05-16 |
Regeneron Pharma |
Composiciones y metodos para expresar el factor ix para terapia para la hemofilia b.
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
US12129223B2
(en)
|
2021-12-16 |
2024-10-29 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023150623A2
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
EP4476331A2
(en)
|
2022-02-07 |
2024-12-18 |
Ensoma, Inc. |
Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
|
|
EP4522210A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
EP4522201A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
EP4561636A1
(en)
|
2022-07-29 |
2025-06-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
EP4619438A2
(en)
|
2022-11-14 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024168253A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Delivery of an rna guided recombination system
|
|
WO2024168265A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Aav delivery of rna guided recombination system
|
|
WO2024197242A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods
|
|
WO2024196965A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
AR133385A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Inserción anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe
|
|
WO2025029654A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025132815A1
(en)
|
2023-12-20 |
2025-06-26 |
Novozymes A/S |
Novel cas nucleases and polynucleotides encoding the same
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|